A comprehensive international study involving nearly 100,000 patients finds no significant link between semaglutide and pancreatic cancer, offering reassurance amid ongoing safety debates.
Semaglutide does not appear to raise the risk of pancreatic cancer, according to research presented at the European Association for the Study of Diabetes annual meeting in Milan. The analysis drew on nationwide registry data from Denmark, Sweden and Norway and followed nearly 100,000 people with type 2 diabetes, offering one of the largest real-world looks yet at a question that has long surrounded GLP-1 medicines.
Led by Einstein Karlstad of the Norwegian Institute of Public Health, the study compared people taking semaglutide with those treated with other commonly used glucose-lowering drugs, including insulin, SGLT2 inhibitors and sulfonylureas. The researchers found no statistically significant difference in pancreatic cancer rates between the groups. They reported 131 cases across 167,399 person-years in the semaglutide group, compared with 123 cases across 140,306 person-years in the control groups, with the pattern holding across Denmark, Sweden and Norway and across different doses and treatment durations.
The findings add to a growing body of evidence suggesting that semaglutide and other GLP-1 receptor agonists are not linked to a measurable increase in pancreatic cancer. A systematic review and meta-analysis published in Diabetes & Metabolic Syndrome, which examined 37 studies involving 46,719 patients, also found no significant rise in pancreatic cancer risk among semaglutide users. A separate meta-analysis of randomised controlled trials in Diabetes, Obesity and Metabolism reached a similar conclusion, saying there was no meaningful overall association between GLP-1 drugs and pancreatic cancer.
That said, researchers continue to urge caution in interpreting the data too narrowly. Diabetes and obesity themselves are known risk factors for pancreatic cancer, which makes it difficult to separate any direct drug effect from the benefits of improved blood sugar control and weight loss. The latest studies may point towards a neutral, or possibly even protective, effect, but experts note that most available follow-up periods still span only a few years, while pancreatic cancer can take much longer to develop. Longer observation will be needed before the debate is considered fully settled.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
